All In Biotech

Free tool

FAERS Monitor: Lumisight

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214511 or its brand name (Lumisight, Pegulicianine Acetate). Reports on generic versions are filed under their own applications.

Reports

8

Serious

4

50% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • flushing4
  • hypersensitivity3
  • paraesthesia3
  • anaphylactic shock2
  • back pain2
  • cardiac arrest2
  • cough2
  • feeling hot2
  • hyperhidrosis2
  • malaise2
  • nausea2
  • acute kidney injury1
  • acute myocardial infarction1
  • anxiety1
  • blood pressure systolic increased1

Reports by year received

View as table
YearReports
20252
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anaphylactic shock2204.061.4227
blood pressure systolic increased1134.821.633
flushingSignal4103.551.7311
acute myocardial infarction189.214.321
feeling hot285.825.894
cardiac arrest263.719.269
paraesthesiaSignal350.120.5100
hypersensitivitySignal342.517.484
hyperhidrosis240.812.343
back pain222.66.823
cough218.85.618
acute kidney injury117.22.73
malaise212.03.611
anxiety19.21.51
nausea26.62.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.